Phase II Window Study on Rituximab in Newly Diagnosed Pediatric Mature B-Cell Non-Hodgkin's Lymphoma and Burkitt Leukemia

Meinhardt, Andrea; Burkhardt, Birgit; Zimmermann, Martin; Borkhardt, Arndt; Kontny, Udo; Klingebiel, Thomas; Berthold, Frank; Janka‐Schaub, Gritta; Klein, Christoph; Kabíčková, Edita; Klapper, Wolfram; Attarbaschi, Andishe; Schrappe, Martin; Reiter, Alfred

doi:10.1200/jco.2009.26.6791

Cited by 172 publications

(118 citation statements)

References 27 publications

Supporting

Mentioning

115

Contrasting

Unclassified

Order By: Relevance

“…Among this group, 64% of patients with BL had a complete or partial response (Griffin et al, 2009). Meinhardt et al (2010) published the results of a pilot window study investigating the upfront usage of rituximab in children with newly diagnosed mature B cell NHL and Burkitt leukaemia. This study demonstrated an approximately 42% response rate to single agent rituximab in children with newly diagnosed, advanced mature B cell lymphoma (Meinhardt et al, 2010).…”

Section: Immunotherapymentioning

confidence: 99%

Risk factors and treatment of childhood and adolescent Burkitt lymphoma/leukaemia

2012

View full text Add to dashboard Cite

SummaryBurkitt lymphoma/leukaemia is the most common (40%) form of non-Hodgkin lymphoma that occurs in children and adolescents. The prognosis of advanced (disseminated) Burkitt lymphoma/leukaemia in children and adolescents three decades ago had a 5-year event-free survival (EFS) of <40%, and required combination chemotherapy and radiation therapy over a 1-2 year period. Currently, the prognosis for the same advanced stage has a 5-year EFS of 85-90% with <6 months of chemotherapy only. Radiation therapy has been eliminated for children and adolescents with Burkitt lymphoma/leukaemia except in emergencies, such as superior vena cava syndrome and acute neurological impairment or in patients with relapse/progression. Current risk factors in the prognosis of childhood and adolescent Burkitt lymphoma/leukaemia include: lactate dehydrogenase level 29 the upper normal limit at diagnosis, bone marrow and central nervous system involvement, poor response to cyclophosphamide, vincristine and prednisone reduction therapy and poor risk cytogenetics. New and novel therapeutic approaches include monoclonal antibody (anti-CD20) therapy, targeted cellular immune therapy and small molecule inhibitors. Future strategies should include improved staging and risk classification, reduction of cytotoxic chemotherapy, the investigation of targeted therapy, an increased understanding of the underlying biology of Burkitt lymphoma/leukaemia, strategies for prevention and approaches to reduce acute and chronic toxicities.

show abstract

Section: Immunotherapymentioning

confidence: 99%

Risk factors and treatment of childhood and adolescent Burkitt lymphoma/leukaemia

2012

View full text Add to dashboard Cite

show abstract

“…Mature B-cell ALL (also called Burkitt leukemia) is rare, accounting for only about 2% to 3% of childhood ALL [Meinhardt et al, 2010].…”

Section: List Of Figuresmentioning

confidence: 99%

Impact of genetic polymorphisms determining leukocyte/neutrophil count on chemotherapy toxicity

et al. 2017

View full text Add to dashboard Cite

“…The feasibility of rituximab was also explored recently in newly diagnosed pediatric patients with mature B-cell NHL and Burkitt leukemia. 23 Rituximab in younger patients with CD20 ϩ B-precursor ALL…”

Section: Rituximab In Mature B-all and Burkitt Nhlmentioning

confidence: 99%

Novel Antibody-Based Therapies For Acute Lymphoblastic Leukemia

Hoelzer

2011

Hematology

View full text Add to dashboard Cite

A major breakthrough in the treatment of acute lymphoblastic leukemia (ALL) was the availability of targeted therapies targeting either specific transcripts, such as bcr-abl fusion protein by tyrosine kinase inhibitors (TKIs), or specific antigens by mAbs. ALL blast cells express a variety of specific antigens (eg, CD19, CD20, CD22, CD33, and CD52) that serve as targets for mAbs. To date, the most data are available for anti-CD20 (rituximab), which has been combined with chemotherapy for the treatment of mature B-ALL/Burkitt lymphoma. Studies with rituximab have also been completed in B-precursor ALL. Another antigen, CD19, is of great interest due to a very high rate of expression in ALL. It can be targeted by a bispecific mAb, blinatumomab, directed against CD19 and CD3. Smaller studies or case reports are also available for the anti-CD52 (alemtuzumab), anti-CD22 (epratuzumab), and anti-CD33 (gemtuzumab) mAbs. Available data demonstrate that mAb therapy in ALL is a highly promising treatment approach. However, several details for an optimal treatment approach, such as the required level of antigen expression, timing, schedule, dosage, and stage of disease, still need to be defined.

show abstract

Phase II Window Study on Rituximab in Newly Diagnosed Pediatric Mature B-Cell Non-Hodgkin's Lymphoma and Burkitt Leukemia

Abstract: Rituximab is active as a single-agent in pediatric B-NHL even though the RR was lower than requested in the phase II plan.

Cited by 172 publications

References 27 publications

Risk factors and treatment of childhood and adolescent Burkitt lymphoma/leukaemia

Risk factors and treatment of childhood and adolescent Burkitt lymphoma/leukaemia

Impact of genetic polymorphisms determining leukocyte/neutrophil count on chemotherapy toxicity

Novel Antibody-Based Therapies For Acute Lymphoblastic Leukemia

Contact Info

Product

Resources

About